Home > Haematology > Triplet therapy for high-risk smoldering myeloma may delay progression to overt disease

Triplet therapy for high-risk smoldering myeloma may delay progression to overt disease


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
JAMA Oncology
Reuters Health - 27/09/2021 - Triplet therapy with carfilzomib, lenalidomide, and dexamethasone (kRD) delayed clinical progression from smoldering myeloma to overt disease in a phase 2 proof-of-principle study. The authors caution that the regimen should not yet be used outside of a clinical trial. "The triplet therapy was evaluated in a population with a median risk of progression to multiple myeloma of about 75% at five years," Dr. Dickran Kazandjian of the Sylvester Comprehensive Cancer Center, University of Miami told Reuters Health by email. "We showed that using the kRD triplet led to a minimal residual disease (MRD)- negative complete response (CR) rate of 70%, which was sustained with a median duration of 5.5 years. Moreover, this clinical benefit directly translated to improvement in the rate of progression to symptomatic overt MM." "We are at an eight-year milestone," he said. "Only 9% of patients have progressed." As reported in JAMA Oncolog...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on